ImmPACT Bio USA INC

7 articles with ImmPACT Bio USA INC

• ImmPACT Bio Names Sylvain Roy as Chief Technology Officer

  5/10/2022

  ImmPACT Bio USA , Inc. today announced the appointment of Sylvain Roy as chief technology officer.

• 

  BioSpace Movers & Shakers: John Maraganore, Larry Alstiel, Brad Margus and More

  4/22/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• ImmPACT Bio Names Venkat Yepuri as Chief Operating Officer

  4/19/2022

  ImmPACT Bio USA , Inc. today announced the appointment of Venkata (Venkat) P. Yepuri as chief operating officer.

• 

  Money on the Move: January 19 – 25

  1/26/2022

  Temps are falling and so is investor cash. Here's which biotech companies are scooping up the dollars this week.

• ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

  1/20/2022

  ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, announced it has closed $111 million in Series B financing, led by venBio Partners along with co-leads Foresite Capital and Decheng Capital.

• 

  ImmPACT Bio Gains $111M, a New Leader and Positive Trial Results

  1/20/2022

  ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.

• ImmPACT Bio Announces Completion of Merger with Kalthera to Progress Next-Generation CAR T Therapies for the Treatment of Cancer

  7/22/2021

  ImmPACT Bio USA, Inc., a company developing novel cell therapies for treating cancer, announced its merger with Kalthera, Inc., a biotechnology company.